The document is a quarterly newsletter from Theralase providing updates on their two divisions - Therapeutic Laser Technology (TLT) and Photo Dynamic Therapy (PDT). It discusses upcoming webinars and seminars, corporate updates including the creation of two operating divisions and identification of bladder cancer as the first clinical target for PDT. It also summarizes partnerships, financing activities, and research progress, including the selection of a leading anti-cancer drug candidate and outlining plans for commercialization and growth.
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
ย
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
Event brochure for the upcoming Clinical Data Standardisation and Managment event in London, June.
The event will feature best practice case studies from CDISC
Frost & Sullivan 2016 Innovation Award Research Summary for New Product Innov...Carestream
ย
Frost and Sullivanโs 10-step process for evaluating candidates for the award.
Frost & Sullivan has awarded Carestream Health its 2016 North America Frost & Sullivan Award for New Product Innovation Leadership for innovation focused on value-based imaging that solves real-life problems and addresses unmet customer needs. This document summarizes the research and processes used by F&S for naming the winner.
Learn more about Carestream Health's medical imaging products at http://www.carestream.com/medical
#Innovation
#Aim2innovate
#winner
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
ย
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
Event brochure for the upcoming Clinical Data Standardisation and Managment event in London, June.
The event will feature best practice case studies from CDISC
Frost & Sullivan 2016 Innovation Award Research Summary for New Product Innov...Carestream
ย
Frost and Sullivanโs 10-step process for evaluating candidates for the award.
Frost & Sullivan has awarded Carestream Health its 2016 North America Frost & Sullivan Award for New Product Innovation Leadership for innovation focused on value-based imaging that solves real-life problems and addresses unmet customer needs. This document summarizes the research and processes used by F&S for naming the winner.
Learn more about Carestream Health's medical imaging products at http://www.carestream.com/medical
#Innovation
#Aim2innovate
#winner
Family Commons, a program of Jewish Child & Family Services, is an inclusive after-school recreation program for individuals of all ages and all abilities.
This is the presentation I used to illustrate a talk I delivered in the BrazTesol One-Day Seminar event in Brasรญlia on March 14, 2014. The idea was to share a little bit of my learning experience in a cMOOC, bringing the subject of open online education to the local radar.
On Wearing Two Hats: Teaching and Responding to WritingClarissa Bezerra
ย
The objective of this session was to raise teachers' awareness of the kind of response to writing that we believe to be in keeping with the principle that writing is a recursive process, non-linear in its creative nature, and the very expression of one's voice. Session presented in the 10th CTJ TEFL Seminar, Brasรญlia, Brazil. July, 2014.
We had 25 minutes as a group (during the June 2011 ETUG Workshop) to come up with an "Elevator Pecha" presentation: 10 slides, 10 seconds each. This is the result of our efforts. All photos are open stock or Creative Commons licensed.
At the 30 July 2012 monthly meeting of APSS (Asia Professional Speakers Singapore) I talked through a slideshow showing snippets from the past year. I've added a commentary here so that people who were unable to attend the meeting can see it too. I hope you enjoy it.
Dom Marcel Lefebvre
04/07/1984. Dom Lefevbre fala a todos os catรณlicos que se sentem desnorteados com a crise da Igreja. Mostra, numa linguagem simples e num texto agradรกvel a legitimidade da defesa da Tradiรงรฃo e a necessidade de guardarmos a fรฉ intacta, rechaรงando o progressismo que muda a doutrina e a fรฉ.
(Ediรงรฃo fora de comรฉrcio)
*
Link: http://catolicosalerta.wordpress.com/2012/07/13/carta-aberta-aos-catolicos-perplexos/
Catรณlicos Alerta!
Folhetos, livros e livretos para propagaรงรฃo da Fรฉ Catรณlica.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com
Family Commons, a program of Jewish Child & Family Services, is an inclusive after-school recreation program for individuals of all ages and all abilities.
This is the presentation I used to illustrate a talk I delivered in the BrazTesol One-Day Seminar event in Brasรญlia on March 14, 2014. The idea was to share a little bit of my learning experience in a cMOOC, bringing the subject of open online education to the local radar.
On Wearing Two Hats: Teaching and Responding to WritingClarissa Bezerra
ย
The objective of this session was to raise teachers' awareness of the kind of response to writing that we believe to be in keeping with the principle that writing is a recursive process, non-linear in its creative nature, and the very expression of one's voice. Session presented in the 10th CTJ TEFL Seminar, Brasรญlia, Brazil. July, 2014.
We had 25 minutes as a group (during the June 2011 ETUG Workshop) to come up with an "Elevator Pecha" presentation: 10 slides, 10 seconds each. This is the result of our efforts. All photos are open stock or Creative Commons licensed.
At the 30 July 2012 monthly meeting of APSS (Asia Professional Speakers Singapore) I talked through a slideshow showing snippets from the past year. I've added a commentary here so that people who were unable to attend the meeting can see it too. I hope you enjoy it.
Dom Marcel Lefebvre
04/07/1984. Dom Lefevbre fala a todos os catรณlicos que se sentem desnorteados com a crise da Igreja. Mostra, numa linguagem simples e num texto agradรกvel a legitimidade da defesa da Tradiรงรฃo e a necessidade de guardarmos a fรฉ intacta, rechaรงando o progressismo que muda a doutrina e a fรฉ.
(Ediรงรฃo fora de comรฉrcio)
*
Link: http://catolicosalerta.wordpress.com/2012/07/13/carta-aberta-aos-catolicos-perplexos/
Catรณlicos Alerta!
Folhetos, livros e livretos para propagaรงรฃo da Fรฉ Catรณlica.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralaseโs proprietary laser technology.
Theralase Technologies Inc. (TSX-V: TLT) announced today the successful results of preclinical studies (in-vitro and in-vivo) demonstrating significant destruction of various brain and colon cancer cell lines. The new proprietary Theralase treatment sharply delayed the tumour progression, when attacked by the Theralase patented light activated Photo Dynamic Compounds (PDCs), signifying a new and broadly promising approach to cancer treatment. When treated with the Theralase PDCs, cancerous mice survived cancer-free for more than 100 days post-treatment, a highly significant milestone.
Theralase's Photo Dynamic Therapy (PDT) Division, announced today study results proving that its patented Photo Dynamic Compounds (PDCs) were significantly more effective in destroying a human urinary bladder carcinoma cell line than a FDA approved photosensitizer, aminolevulinic acid (ALA).
UV6418 Rev. May 20, 2014 This case was prepared .docxdickonsondorris
ย
UV6418
Rev. May 20, 2014
This case was prepared by Alex Droznik (MBA โ11) and Susan Chaplinsky, Professor of Business Administration. It
was written as a basis for class discussion rather than to illustrate effective or ineffective handling of an
administrative situation. Copyright ๏ฃ 2011 by the University of Virginia Darden School Foundation, Charlottesville,
VA. All rights reserved. To order copies, send an e-mail to [emailย protected] No part of this
publication may be reproduced, stored in a retrieval system, used in a spreadsheet, or transmitted in any form or by
any meansโelectronic, mechanical, photocopying, recording, or otherwiseโwithout the permission of the Darden
School Foundation.
RADNET, INC.: FINANCING AN ACQUISITION
In July 2006, Mark Stolper, CFO of RadNet, Inc., finally hung up the phoneโit had been
a long conversation. RadNet was in the process of making the largest acquisition in the
companyโs 25-year history. The acquisition of Radiologix would make the combined firms the
largest private diagnostic imaging provider in the United States. At the moment, the pressing
issue was the financing for the acquisition. Stolper had been working for weeks with a team of
capital market professionals at GE Capital, a commercial lender catering to health care
companies, and with merger and acquisition (M&A) bankers at Jefferies, a Wall Street
investment bank. Each had proposed somewhat different financing arrangements for the
acquisition. For some time, RadNet had been highly leveraged from debt taken on to purchase
the necessary imaging equipment to support its growth.1 The board of directors had hired Stolper
in 2003 in large part to supervise a restructuring process to improve RadNetโs financial position.
At the time, he had found a company with โtoo much debt, and the wrong kind of debt.โ2 In the
interim, he took several steps to refinance and renegotiate the terms of existing debt to improve
the companyโs financial footing and help the company grow out of its debt burden. He viewed
the Radiologix acquisition as a potentially transformative opportunity that would spur growth
and further enhance the companyโs operating flexibility and long-term financial stability.
Reasoning through the proposed financing arrangements went beyond the issues of price
and availability to include how the arrangements might affect operating flexibility, repayment
ease, and even the composition of the firmโs investors. The phone call was his final consultation
with GE Capital and Jefferies; the next day, he would need to make his recommendation to
RadNetโs board about the acquisition financing.
1 Magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT)
machines typically cost between several hundred thousand dollars to over one million dollars, depending on the
technological sophistication of the machine.
2 Case ...
2014 Overview of significant trends in the life sciences (Biotechnology, Pharmaceutical, Device and Diagnostics) industry with Big Data in the Life Sciences featured articles.
1. Production, marketing and distribution of the TLC-1000 and TLC-2000 Theralase Superpulsed Laser Technology for sale to healthcare practitioners nationally and internationally, interested in the safe and effective treatment of neuromuscular skeletal conditions through the elimination of pain and inflammation and the accelerated regeneration of tissue.
2. Commercialization of the patented TLC-3000 Laser and Photo Dynamic Compound Technology platform through preclinical research, FDA clinical trials and new technology development in the direct destruction of cancers for oncological applications and in the destruction of bacteria for sterilization of medical and food processing facilities.
Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in healing injured tissue and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint injuries in both humans and animals. Theralase complies with all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high quality products. Theralase is actively developing patented Photo Dynamic Compound (PDC) technology that is able to target and destroy cancers, bacteria and viruses when light activated by Theralase's proprietary and patented laser technologies.
Low Level Laser Therapy (LLLT) is a fast growing field of medicine recognized by every major industrialized nation in the world, offering painless, non-invasive and highly effective drug-free solutions. Able to treat a plethora of neural muscular skeletal conditions, LLLT is often the only solution that is available to the highly trained practitioner to control disease when conventional therapies have come up lacking.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralaseโs proprietary and patented laser technology.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralaseโs proprietary and patented laser technology.
Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralaseโs proprietary and patented laser technology.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase complies with FDA, Health Canada, CE, ISO-13485 and CSA-601 regulatory approvals to ensure efficacy, safety and quality in manufacture. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralaseโs proprietary and patented laser technology.
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit www.theralase.com 1-866-843-5273
Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
Memorandum Of Association Constitution of Company.pptseri bangash
ย
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
ย
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
ย
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Skye Residences | Extended Stay Residences Near Toronto Airportmarketingjdass
ย
Experience unparalleled EXTENDED STAY and comfort at Skye Residences located just minutes from Toronto Airport. Discover sophisticated accommodations tailored for discerning travelers.
Website Link :
https://skyeresidences.com/
https://skyeresidences.com/about-us/
https://skyeresidences.com/gallery/
https://skyeresidences.com/rooms/
https://skyeresidences.com/near-by-attractions/
https://skyeresidences.com/commute/
https://skyeresidences.com/contact/
https://skyeresidences.com/queen-suite-with-sofa-bed/
https://skyeresidences.com/queen-suite-with-sofa-bed-and-balcony/
https://skyeresidences.com/queen-suite-with-sofa-bed-accessible/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-king-queen-suite-with-sofa-bed/
https://skyeresidences.com/2-bedroom-deluxe-queen-suite-with-sofa-bed-accessible/
#Skye Residences Etobicoke, #Skye Residences Near Toronto Airport, #Skye Residences Toronto, #Skye Hotel Toronto, #Skye Hotel Near Toronto Airport, #Hotel Near Toronto Airport, #Near Toronto Airport Accommodation, #Suites Near Toronto Airport, #Etobicoke Suites Near Airport, #Hotel Near Toronto Pearson International Airport, #Toronto Airport Suite Rentals, #Pearson Airport Hotel Suites
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
ย
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
Business Valuation Principles for EntrepreneursBen Wann
ย
This insightful presentation is designed to equip entrepreneurs with the essential knowledge and tools needed to accurately value their businesses. Understanding business valuation is crucial for making informed decisions, whether you're seeking investment, planning to sell, or simply want to gauge your company's worth.
"๐ฉ๐ฌ๐ฎ๐ผ๐ต ๐พ๐ฐ๐ป๐ฏ ๐ป๐ฑ ๐ฐ๐บ ๐ฏ๐จ๐ณ๐ญ ๐ซ๐ถ๐ต๐ฌ"
๐๐ ๐๐จ๐ฆ๐ฌ (๐๐ ๐๐จ๐ฆ๐ฆ๐ฎ๐ง๐ข๐๐๐ญ๐ข๐จ๐ง๐ฌ) is a professional event agency that includes experts in the event-organizing market in Vietnam, Korea, and ASEAN countries. We provide unlimited types of events from Music concerts, Fan meetings, and Culture festivals to Corporate events, Internal company events, Golf tournaments, MICE events, and Exhibitions.
๐๐ ๐๐จ๐ฆ๐ฌ provides unlimited package services including such as Event organizing, Event planning, Event production, Manpower, PR marketing, Design 2D/3D, VIP protocols, Interpreter agency, etc.
Sports events - Golf competitions/billiards competitions/company sports events: dynamic and challenging
โญ ๐ ๐๐๐ญ๐ฎ๐ซ๐๐ ๐ฉ๐ซ๐จ๐ฃ๐๐๐ญ๐ฌ:
โข 2024 BAEKHYUN [Lonsdaleite] IN HO CHI MINH
โข SUPER JUNIOR-L.S.S. THE SHOW : Th3ee Guys in HO CHI MINH
โขFreenBecky 1st Fan Meeting in Vietnam
โขCHILDREN ART EXHIBITION 2024: BEYOND BARRIERS
โข WOW K-Music Festival 2023
โข Winner [CROSS] Tour in HCM
โข Super Show 9 in HCM with Super Junior
โข HCMC - Gyeongsangbuk-do Culture and Tourism Festival
โข Korean Vietnam Partnership - Fair with LG
โข Korean President visits Samsung Electronics R&D Center
โข Vietnam Food Expo with Lotte Wellfood
"๐๐ฏ๐๐ซ๐ฒ ๐๐ฏ๐๐ง๐ญ ๐ข๐ฌ ๐ ๐ฌ๐ญ๐จ๐ซ๐ฒ, ๐ ๐ฌ๐ฉ๐๐๐ข๐๐ฅ ๐ฃ๐จ๐ฎ๐ซ๐ง๐๐ฒ. ๐๐ ๐๐ฅ๐ฐ๐๐ฒ๐ฌ ๐๐๐ฅ๐ข๐๐ฏ๐ ๐ญ๐ก๐๐ญ ๐ฌ๐ก๐จ๐ซ๐ญ๐ฅ๐ฒ ๐ฒ๐จ๐ฎ ๐ฐ๐ข๐ฅ๐ฅ ๐๐ ๐ ๐ฉ๐๐ซ๐ญ ๐จ๐ ๐จ๐ฎ๐ซ ๐ฌ๐ญ๐จ๐ซ๐ข๐๐ฌ."
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
ย
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
ย
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. Youโll also learn
โข Four (4) workplace discipline methods you should consider
โข The best and most practical approach to implementing workplace discipline.
โข Three (3) key tips to maintain a disciplined workplace.
1. Q3 - September 2012
THERALASE
QUARTERLY NEWSLETTER
An update for clients, investors and employees
UPCOMING WEBINARS
October 23, 2012 November 27, 2012
Clinical and Business Rewards of Using Laser in Practice Current Research in Low Level Laser Therapy
To register To register
https://www2.gotomeeting.com/register/793806762 https://www2.gotomeeting.com/register/415407642
UPCOMING SEMINARS
Theralaseโs Dr. Rhonda Mostyn will be presenting โModern Science, Classic Healing: Therapeutic Laser Therapy and
Chiropracticโ at Parker Seminars Toronto on Friday, September 21, 2012 at 11:00 am.
CORPORATE UPDATES
Theralase Creates Two Operating Divisions
On August 16, 2012, Theralase announced that it is reorganizing its operations into two separate reportable operating
divisions to better service and focus the company's resources for both independent markets. The Therapeutic Laser
Technology (TLT) division will be responsible for all aspects of the Company's burgeoning therapeutic laser business,
which manufactures products used by healthcare practitioners predominantly for the healing of pain and the Photo
Dynamic Therapy (PDT) division, which researches and develops Photo Dynamic Compounds (PDCs) for the
destruction of primarily cancer.
It has become evident through the recent successes of both technology platforms that these two operating divisions have
unique requirements in terms of financing, staffing, logistics and resource allocation. Our intent is to manage and focus
the direction of each division to better execute on their respective strategic objectives. Theralase's mandate is to build
both the TLT and PDT divisions into separate $50 million annual recurring revenue models within the next 5 to 7 years.
Photo Dynamic Therapy PDT division
There exists a substantial stream of research on the amount of systemic cytotoxic drugs and physical modalities
associated with different types of radiation therapy. Despite its many successes, and in spite of decades of advanced
research with highly sophisticated instrumentation, it has not solved many of the basic mysteries of cancer. Worse yet,
every gain seems to be more than offset by additional serious problems and contradictions.
Theralase Inc., therefore, offers an innovative Photodynamic therapy (PDT) paradigm and patented approach for the
novel anti-cancer technology platform.
2. Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective
cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by
irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of
events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction.
Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with
inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects,
greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as
organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments.
However, contemporary PDT produces mostly superficial effects. Due to a limited light penetration through tissues, the
depth of tumor destruction ranges from a few millimeters to up to 1 centimeter. Theralaseโs breaking-ground technology
offers a complete illumination of this apparent disadvantage. Therefore, Theralaseโs technology platform, which offers a
number of significant technological improvements and a barrier-breaking innovation, has the potential to become the first
PDT integrated into the mainstream of cancer treatment.
Theralase Identifies the First Cancer Target for its
Advanced Photo Dynamic Therapy
On July 18, 2012, Theralase announced that it has selected Theralase plans to aggressively pursue commercialization
bladder cancer as the first clinical target in its Novel Photo of our ground-breaking PDC technology through the
Dynamic Compound (PDC) research. Theralase now has accelerated FDA regulatory approval process. Theralase
a clear direction with which to proceed with FDA Clinical feels its technology will prove as effective in bladder
Trials. Bladder cancer is the fifth most common cancer in cancer preclinical trials that will eventually lead to FDA
North America being the fourth most common in men and clinical approval.
the eighth most common in woman. In North America, it is
estimated that there will be over 77,000 new cases and Theralase Accelerates Intellectual Property Strategy
over 15,000 deaths annually.
On April 13, 2012, Theralase Technologies Inc. announced
that it has filed a patent application for a newly developed
Photo Dynamic Compound (PDC) to be added to its
library of patented Photo Dynamic Compounds. It has
been a stated objective to build on these important
existing holdings and continue to expand the Intellectual
Property footprint of the corporation. This filing represents
a significant step in this regard and will specifically target
new avenues in the destruction of cancers, bacteria and
viruses.
"I had indicated to our shareholders that we would quickly
show evidence of our IP strategy," said Roger
Dumoulin-White, CEO of Theralase Technologies. "We
The Theralase light activated PDC drug has been proven
firmly believe that our patents will be invaluable to
to be superior to any currently approved FDA PDC drug
Theralase as we continue to execute on our growth plan
on the market, tested in Theralaseโs lab and we are working
on the road to commercialization.โ
hard to help eliminate this devastating disease that can
dramatically affect so many families.
3. Mr. White added, โFurther to our press release of March 28, 2012, I am pleased to say that the mice, with under the skin
colon cancer tumours treated with Theralaseโs patented anti-cancer PDC technologies have survived and flourished
forty-eight days post treatment; the mice continue to be cancer free. Based on recent successes in our research, we are
confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future.โ
Theralase Identifies Leading Anti-Cancer Drug Candidate
On March 14, 2012, Theralase Technologies Inc. announced that it is pursuing FDA Phase 1 approval for its patented
Photo Dynamic Compounds (PDCs).
Theralase has successfully identified the leading drug candidate, which will be used for safety and efficacy clinical testing
in human cancer patients. In multiple preclinical studies, the leading drug candidate has been selected from Theralaseโs
library of PDCs and has repeatedly demonstrated:
โข extremely high efficacy, virtually 100% kill rate, in various cancer cell lines including brain and colorectal cancers
โข robust destruction of subcutaneous (under the skin) cancerous tumours in animals
โข extremely low toxicity
โข high stability, allowing for a long shelf life
The preclinical results were reviewed by SPIE (The International Society for Optics and Photonics) and were accepted by
the Conference Chairs for presentation at the SPIE Photonics Europe conference in Brussels, Belgium.
Theralase will validate its extensive data with additional cancer animal models and toxicology analyses. This will provide
the results required by the FDA to design a FDA Phase 1 clinical human study to commence in 2013 with scheduled
completion in 2014.
Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "Achievement of this critical milestone represents
irrefutable proof that the Theralase leading drug PDC candidate is effective in the destruction of cancer in live animal
models. The treatment was well tolerated by the animals, eliminating their cancer without any adverse effects. The
Theralase leading drug candidate has been proven to be superior to any currently approved FDA PDC drug on the
market, tested in our lab.โ
Theralase Featured on "The Next Biggest Winner" Business TV Series
Theralase was featured on "The Next Biggest Winner", a television series devoted to discovering undervalued companies
with the ability to grow significantly in shareholder value and become a big winner as an investment opportunity.
The TV show, "The Next Biggest Winner," which showcases companies with significant growth potential scheduled an
in-depth interview with Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. on the iChannel,
Tuesday, August 14th at 7:30pm. The iChannel has over 1.3 million affluent Canadian subscribers who look to its business
programming for new investment opportunities.
To view the interview, please visit
http://www.thenextbiggestwinner.com/theralase-technologies-inc/
4. Therapeutic Laser Technology (TLT) division
Low Level Laser Therapy (LLLT) is the drug-free, non-invasive and safe (FDA recognised) clinical application of light in
the range of 1mW โ 500mW to a patient to promote tissue regeneration, reduce inflammation and relieve pain. Theralase
technology is the only product on the market that activates all three known cellular pathways (ATP production, iNOS
production and Na+ / K+ pump regulation) and provides a depth of penetration of four inches into tissue. Theralase
technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal
conditions and wound healing. The White Paper โUNDERSTANDING THE MECHANISMS OF LOW LEVEL
LASER THERAPY (LLLT)โ may be accessed from the Theralase website and offers independent clinical studies to
support the science.
Theralase Establishes Middle East Distribution
Network
On May 30, 2012, Theralase Technologies Inc. announced BioFinance is a leading life sciences investor conference in
that it had entered into an exclusive distribution Canada, which highlights more than 60 diverse life science
agreement with Jordan based medical device distributor companies, and the investment opportunities that they
MediQu to market and sell the Theralase line of present. BioFinance 2012 also featured 17 investor
therapeutic medical lasers into the Middle East, branded presentations that are aimed at addressing specific
as Theralase Arabia. financing and management related issues relevant to life
science industries.
Under the terms of the agreement, MediQu will
exclusively market and sell the Theralase therapeutic Theralaseโs presentation took place Wednesday, May 30th
medical laser technology in Jordan, Lebanon, Syria, Iraq, at the St. Andrewโs Club and Conference Center. Mr.
Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Roger Dumoulin-White, President and CEO of Theralase
Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, presented on the strategic direction and recent
Tunisia, Mauritania and Morocco, in exchange for accomplishments of the company followed by a short
achievement of certain minimum performance criteria. Q&A period and one-on-one meetings with investors.
MediQu is a large medical device distribution company in Theralase Closes Equity Financing
the Middle East that has partnered with Theralase to
On April 13, 2012 Theralase Technologies Inc. stated that it
establish Theralase Arabia bringing to the table an
has closed a previously announced private placement (the
impressive array of government, commercial and medical
"Private Placement") of 3,000,000 units (the "Units") at a
contacts including numerous major hospitals, medical
price of Cdn $0.25 per Unit for gross proceeds of CDN
clinics and doctors in the region. Theralase Arabia expects
$750,000.00. Each Unit consists of one common share in
to exceed USD $5 million annually in the Middle East
the capital of the Company and one-half of one
within 3 to 5 years of launch.
non-transferable common share purchase warrant (a
"Warrant"). Each whole Warrant entitles the purchaser to
Theralase Presents at BioFinance 2012 Life purchase one additional common share (a "Warrant
Sciences Conference Share") in the capital of the Company until April 13, 2013 at
Roger Dumoulin-White, President and CEO presented a price of CDN $0.38 per Warrant Share. The securities
the latest corporate information at the BioFinance 2012 issued under the Private Placement including any shares
conference held in Toronto, Ontario from May 29 to 30, issued upon exercise of the Warrants are subject to a four
2012. month hold period, expiring August 13, 2012.
5. The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the
Company's prospects in a number of areas; specifically:
โข Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health
Network
โข Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser
technology in the destruction of bacteria and viruses
โข TLC-1000 and TLC-900 therapeutic medical laser USA sales and marketing expansion
โข TLC-1000 therapeutic medical laser incorporating TENS (Transcutaneous Electrical Nerve Stimulation)
โข TLC-2000 therapeutic medical biofeedback laser commercialization
OUTLOOK
Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the TLC-900
controllerless laser series in the Canadian, US and international markets in 2012, supported by new independent scientific
research confirming the effectiveness of Theralaseโs proprietary and patented technology. Theralase will commercialize
its patented TLC-2000 Biofeedback technology for launch in the first quarter of 2013, while researching and developing
its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.
The groundwork has been laid for significant growth. Our proven patented technology has no equal and our ability to
dramatically scale sales and marketing geographically as well as demographically will allow Theralase significant first
mover market advantage. Theralase is currently debt free as it utilizes its profits from the sale of its TLC-1000 and
TLC-900 Therapeutic Medical Laser platforms to pay for its future growth in the form of the launch of the TLC-2000
Biofeedback Therapeutic Laser Technology and the commercialization of the TLC-3000 Photo Dynamic Compound
Cancer Destruction Technology.
This newsletter contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
For more information, please contact:
Roger Dumoulin-White Kristina Hachey
President & CEO, Chief Financial Officer
416-447-8455 ext. 225 416-447-8455 ext. 224
rwhite@theralase.com khachey@theralase.com
Greg Bewsh Dr. Arkady Mandel
Director of Investor Relations, Chief Scientific Officer
416-447-8455 ext. 262 416-447-8455 ext. 242
gbewsh@theralase.com amandel@theralase.com